RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
selpercatinib Sensitive: A1 - Approval
|
selpercatinib Sensitive: A1 - Approval
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
pralsetinib Sensitive: A1 - Approval
|
pralsetinib Sensitive: A1 - Approval
|
RET mutation
|
Thyroid Gland Anaplastic Carcinoma
|
RET mutation
|
Thyroid Gland Anaplastic Carcinoma
|
selpercatinib Sensitive: A2 - Guideline
|
selpercatinib Sensitive: A2 - Guideline
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
TPX-0046 Sensitive: C2 – Inclusion Criteria
|
TPX-0046 Sensitive: C2 – Inclusion Criteria
|
RET mutation
|
NSCLC
|
RET mutation
|
NSCLC
|
TPX-0046 Sensitive: C2 – Inclusion Criteria
|
TPX-0046 Sensitive: C2 – Inclusion Criteria
|
RET mutation
|
NSCLC
|
RET mutation
|
NSCLC
|
BOS-172738 Sensitive: C2 – Inclusion Criteria
|
BOS-172738 Sensitive: C2 – Inclusion Criteria
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
BOS-172738 Sensitive: C2 – Inclusion Criteria
|
BOS-172738 Sensitive: C2 – Inclusion Criteria
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET inhibitor Sensitive: C3 – Early Trials
|
RET inhibitor Sensitive: C3 – Early Trials
|
RET mutation
|
NSCLC
|
RET mutation
|
NSCLC
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
RET mutation
|
Melanoma
|
RET mutation
|
Melanoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
RET mutation
|
Thyroid Gland Carcinoma
|
RET mutation
|
Thyroid Gland Carcinoma
|
LDD-2633 Sensitive: D – Preclinical
|
LDD-2633 Sensitive: D – Preclinical
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RET mutation
|
Thyroid Gland Medullary Carcinoma
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
RTB101 + RAF265 Sensitive: D – Preclinical
|
RET mutation
|
Thyroid Gland Carcinoma
|
RET mutation
|
Thyroid Gland Carcinoma
|
CB-228 + AST-487 Sensitive: D – Preclinical
|
CB-228 + AST-487 Sensitive: D – Preclinical
|
RET mutation
|
Thyroid Gland Carcinoma
|
RET mutation
|
Thyroid Gland Carcinoma
|
AST-487 Sensitive: D – Preclinical
|
AST-487 Sensitive: D – Preclinical
|